A Pfizer Analyst's 3 Possible Coronavirus Vaccine Readout Scenarios

The first Interim data from an ongoing, late-stage coronavirus trial by Pfizer Inc. PFE is expected sometime after the U.S. presidential elections, according to an analyst at Cantor Fitzgerald.

The Pfizer Analyst: Louise Chen has an Overweight rating and $53 price target for Pfizer shares.

The Pfizer Thesis: Pfizer plans to report the results if they are definitive — achieving 76.9% or more efficacy in 32 total number of cases, or if the vaccine fails, Chen said in a Monday note.

The potential stock reaction to a vaccine readout will in part hinge on macro factors and competing vaccines and treatments, the analyst said.

She discussed three possible scenarios for the vaccine readout and outlined how Pfizer's stock could trade under each one. 

Related Link: The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings

If Pfizer reports positive data at the first interim analysis, the company's shares will trade higher, with all else being equal, Chen said.

If the vaccine candidate becomes a worldwide, recurring revenue stream for Pfizer, it will likely augment net present value by about $5 per share, the analyst said. 

Under the second scenario of Pfizer reporting positive efficacy data and the vaccine being only a one-time benefit for the company, $2 per share will accrue to the net present value, she sad.

A one-time benefit means that once everyone is vaccinated, then there is no longer a recurring revenue stream to the company, Chen said. 

Under the third scenario of the vaccine candidate failing, Pfizer shares would lose about $4, the analyst said.

"This is because FactSet consensus already has $1.4B of sales for PFE's COVID-19 vaccine in 2020, $8.7B in 2021 and ~$2.1B annually, thereafter."

PFE Price Action: At last check, Pfizer shares were down 2.11% at $36.23.

Related Link: Moderna Bull, Bear On Q3 Report, Coronavirus Vaccine Timeline

Posted In: Cantor FitzgeraldCoronavirusCovid-19Louise ChenvaccineAnalyst ColorBiotechHealth CarePrice TargetReiterationAnalyst RatingsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.